Carta Biosciences

Curated by Signal

Provider of genomic testing for in vitro fertilization

Overview

Provider of genomic testing for in vitro fertilization. The company offers advanced genomic testing for IVF tests to predict embryo disease risk and health outcomes in advance. It offers tests for Aneuploidy, Polygenic, and Monogenic.

Key facts

Founded: 2018
Headquarters: London, United Kingdom
Stage: Sign up to view
Industry: Life Sciences Technology

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

42Genetics
Provider of a platform for NGS data analysis
Life Sciences TechnologyBelfast, United Kingdom
Her.9
Provider of dietary supplements for women health
Life Sciences TechnologyLondon, United Kingdom
NESO Technology
Developer of screening devices for the treatment of neural impairment
Life Sciences TechnologyLondon, United Kingdom

About Carta Biosciences

What does Carta Biosciences do?

Provider of genomic testing for in vitro fertilization.

Where is Carta Biosciences headquartered?

Carta Biosciences is headquartered in London, United Kingdom.

When was Carta Biosciences founded?

Carta Biosciences was founded in 2018.

Which sector is Carta Biosciences in?

Carta Biosciences operates in Life Sciences Technology.

Who are Carta Biosciences's competitors?

Companies similar to Carta Biosciences include 42Genetics, Her.9, and NESO Technology.